Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 67


Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases.

Adegunsoye A, Levy M, Oyenuga O.

Biomed Res Int. 2015;2015:929170. doi: 10.1155/2015/929170. Epub 2015 Oct 25. Review.


Managing comorbidities in idiopathic pulmonary fibrosis.

Fulton BG, Ryerson CJ.

Int J Gen Med. 2015 Sep 22;8:309-18. doi: 10.2147/IJGM.S74880. eCollection 2015. Review.


Fibrogenesis: Mechanisms, Dynamics and Clinical Implications.

Wilson MD.

Iran J Pathol. 2015 Spring;10(2):83-8. Review. No abstract available.


Pulmonary hypertension: diagnostic and therapeutic challenges.

Bazan IS, Fares WH.

Ther Clin Risk Manag. 2015 Aug 17;11:1221-33. doi: 10.2147/TCRM.S74881. eCollection 2015. Review.


Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers.

Trammell AW, Pugh ME, Newman JH, Hemnes AR, Robbins IM.

Pulm Circ. 2015 Jun;5(2):356-63. doi: 10.1086/681264.


Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies.

Juarez MM, Chan AL, Norris AG, Morrissey BM, Albertson TE.

J Thorac Dis. 2015 Mar;7(3):499-519. doi: 10.3978/j.issn.2072-1439.2015.01.17. Review.


Prognostic value of cardiovascular magnetic resonance derived right ventricular function in patients with interstitial lung disease.

Kato S, Sekine A, Kusakawa Y, Ogura T, Futaki M, Iwasawa T, Kirigaya H, Gyotoku D, Iinuma N, Iguchi K, Nakachi T, Fukui K, Kimura K, Umemura S.

J Cardiovasc Magn Reson. 2015 Feb 11;17:10. doi: 10.1186/s12968-015-0113-5.


High-mobility group box-1 induces vascular remodelling processes via c-Jun activation.

Zabini D, Crnkovic S, Xu H, Tscherner M, Ghanim B, Klepetko W, Olschewski A, Kwapiszewska G, Marsh LM.

J Cell Mol Med. 2015 May;19(5):1151-61. doi: 10.1111/jcmm.12519. Epub 2015 Feb 28.


Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience.

Kundu S, Mitra S, Ganguly J, Mukherjee S, Ray S, Mitra R.

Lung India. 2014 Oct;31(4):354-60. doi: 10.4103/0970-2113.142115.


Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis.

DePianto DJ, Chandriani S, Abbas AR, Jia G, N'Diaye EN, Caplazi P, Kauder SE, Biswas S, Karnik SK, Ha C, Modrusan Z, Matthay MA, Kukreja J, Collard HR, Egen JG, Wolters PJ, Arron JR.

Thorax. 2015 Jan;70(1):48-56. doi: 10.1136/thoraxjnl-2013-204596. Epub 2014 Sep 12.


Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis.

Oda K, Ishimoto H, Yamada S, Kushima H, Ishii H, Imanaga T, Harada T, Ishimatsu Y, Matsumoto N, Naito K, Yatera K, Nakazato M, Kadota J, Watanabe K, Kohno S, Mukae H.

Respir Res. 2014 Sep 1;15:109. doi: 10.1186/s12931-014-0109-y.


Pulmonary hypertension and right heart dysfunction in chronic lung disease.

Zangiabadi A, De Pasquale CG, Sajkov D.

Biomed Res Int. 2014;2014:739674. doi: 10.1155/2014/739674. Epub 2014 Jul 24. Review.


New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.

Ahluwalia N, Shea BS, Tager AM.

Am J Respir Crit Care Med. 2014 Oct 15;190(8):867-78. doi: 10.1164/rccm.201403-0509PP. Review.


Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension due to lung diseases and/or hypoxia.

Sakkijha H, Idrees MM.

Ann Thorac Med. 2014 Jul;9(Suppl 1):S56-61. doi: 10.4103/1817-1737.134030.


Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?

Nathan SD, King CS.

Drug Des Devel Ther. 2014 Jul 2;8:875-85. doi: 10.2147/DDDT.S64907. eCollection 2014. Review.


Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia.

Corte TJ, Keir GJ, Dimopoulos K, Howard L, Corris PA, Parfitt L, Foley C, Yanez-Lopez M, Babalis D, Marino P, Maher TM, Renzoni EA, Spencer L, Elliot CA, Birring SS, O'Reilly K, Gatzoulis MA, Wells AU, Wort SJ; BPHIT Study Group.

Am J Respir Crit Care Med. 2014 Jul 15;190(2):208-17. doi: 10.1164/rccm.201403-0446OC.


Impact of pulmonary hypertension on exercise performance in patients with interstitial lung disease undergoing evaluation for lung transplantation.

Armstrong HF, Schulze PC, Bacchetta M, Thirapatarapong W, Bartels MN.

Respirology. 2014 Jul;19(5):675-82. doi: 10.1111/resp.12306. Epub 2014 May 6.


Intrinsic defence capacity and therapeutic potential of natriuretic peptides in pulmonary hypertension associated with lung fibrosis.

Baliga RS, Scotton CJ, Trinder SL, Chambers RC, MacAllister RJ, Hobbs AJ.

Br J Pharmacol. 2014 Jul;171(14):3463-75. doi: 10.1111/bph.12694.


Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial.

Seyfarth HJ, Hammerschmidt S, Halank M, Neuhaus P, Wirtz HR.

Pulm Circ. 2013 Sep;3(3):632-8. doi: 10.1086/674311. Epub 2013 Nov 19.


An official American Thoracic Society Statement: pulmonary hypertension phenotypes.

Dweik RA, Rounds S, Erzurum SC, Archer S, Fagan K, Hassoun PM, Hill NS, Humbert M, Kawut SM, Krowka M, Michelakis E, Morrell NW, Stenmark K, Tuder RM, Newman J; ATS Committee on Pulmonary Hypertension Phenotypes.

Am J Respir Crit Care Med. 2014 Feb 1;189(3):345-55. doi: 10.1164/rccm.201311-1954ST.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk